Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

News provided by

Jul 21, 2014, 11:05 ET

NEW YORK, July 21, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

http://www.reportlinker.com/p02242718/Critical-Care-Therapeutics-in-Major-Developed-Markets-to-2020---New-and-Late-Stage-Four-Factor-PCCs-and-Recombinant-Products-to-Drive-Market.html

Summary

GBI Research, the leading business intelligence provider, has released its latest research: "Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market", which provides in-depth analysis of the critical care market in the US, UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market forecasts to 2020. It covers critical care indications that are being treated using the five major plasma-derived products of albumin, anti-thrombin concentrates, factor XIII concentrates, fibrinogen concentrates, and prothrombin complex concentrates.

The total value of the critical care market in the major developed markets was estimated at $1.8 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.7% to $2.5 billion in 2019. This growth is attributed to the recent approval of new factor concentrates in the US that are expected to witness increasing uptake in the forecast period. Factor concentrates are increasingly preferred due to their lower infection risks over older alternatives such as FFP and cryoprecipitate in critical care settings.

The US accounts for the largest share (41%) of the global critical care market and is expected to post high growth at a CAGR of 7.5% until 2020. KCentra, the first four-factor PCC in the US, and Tretten, the first recombinant FXIII concentrate, were approved in 2013 and are expected to witness good uptake in the forecast period. Two additional factor concentrates approved in the US in 2009 - RiaStap (human fibrinogen concentrate) and ATryn (recombinant AT concentrate) - are also expected to increase their uptake, which will contribute to market growth. With no new significant launches in the forecast period, the European market is estimated to witness much slower growth, with the UK at a CAGR of 3.0%, France at 2.5%, Germany and Spain both at 2.3%, and Italy at 2.0%

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in critical care in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada.The report includes -
- A brief introduction to the five major plasma-derived products in critical care and the indications that they are being used to treat, as well as disease overview, epidemiology, other treatment options, and treatment patterns
- Analysis of major marketed products in critical care, covering product performance in terms of the safety and efficacy of recent approvals
- A review of the critical care pipeline, including individual analysis of promising late-stage pipeline drugs that are most likely to enter the market during the forecast period
- Multi-scenario forecasts of the critical care market over the 2013–2020 period in the eight major developed markets
- Key drivers and restraints that have had and are expected to have a significant impact on the market
- An overview of major licensing and co-development agreements that could affect growth trends

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to markets with high growth potential
- Develop market entry and expansion strategies by identifying the regions and therapeutic segments poised for strong growth
- Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the critical care drugs market
- Develop key strategic initiatives based on an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Albumin in Critical Care 9
2.1.1 Overview 9
2.1.2 Diseases or Conditions Indicated for Albumin 9
2.1.3 Epidemiology 10
2.1.4 Other Treatment Options 10
2.1.5 Treatment Patterns 10
2.2 Anti-Thrombin III Concentrates in Critical Care 11
2.2.1 Overview 11
2.2.2 Anti-Thrombin Deficiencies 11
2.2.3 Epidemiology 11
2.2.4 Treatment Options 12
2.2.5 Treatment Patterns 12
2.3 Factor XIII Concentrates in Critical Care 12
2.3.1 Overview 12
2.3.2 FXIII Deficiencies 13
2.3.3 Epidemiology 13
2.3.4 Treatment Options 13
2.3.5 Treatment Patterns 13
2.4 Fibrinogen Concentrates in Critical Care 14
2.4.1 Overview 14
2.4.2 Fibrinogen Deficiencies 14
2.4.3 Epidemiology 15
2.4.4 Treatment Options 15
2.4.5 Treatment Patterns 15
2.5 Prothrombin Complex Concentrate in Critical Care 16
2.5.1 Overview 16
2.5.2 Diseases or Conditions Indicated for Prothrombin Complex Concentrate 16
2.5.3 Epidemiology 17
2.5.4 Treatment Options 17
2.5.5 Treatment Patterns 18
3 Therapeutic Landscape 19
3.1 Albumin Products 19
3.1.1 Buminate (albumin, human) - Baxter 19
3.1.2 Zenalb (human albumin) - Bio Products Laboratory 19
3.1.3 Human Albumin Biotest (albumin, human) - Biotest 19
3.1.4 AlbuRx (albumin) - CSL Behring 19
3.1.5 Albuminar (albumin, human) 5% - CSL Behring 20
3.1.6 Albutein (albumin (human)) - Grifols 20
3.1.7 Albuked (human albumin) - Kedrion 20
3.1.8 Vialebex (human albumin) - French Fractionation and Biotechnology Laboratory 21
3.1.9 Albunorm (human albumin) - Octapharma 21
3.1.10 Alburaas (human albumin) - Shanghai RAAS 21
3.2 Anti-Thrombin Concentrates 21
3.2.1 Atryn (antithrombin alfa) - rEVO Biologics 21
3.2.2 Thrombate III (AT III human) - Grifols 23
3.2.3 Anbinex (AT III human) - Grifols 23
3.2.4 Kybernin P (AT III human) - CSL Behring 23
3.2.5 Aclotine (AT III, human) - French Fractionation and Biotechnology Laboratory 24
3.2.6 Anti-Thrombin III (AT III human) - Baxter 24
3.2.7 AT III Kedrion (AT III human) - Kedrion 24
3.2.8 Neuart (AT III, human) - Mitsubishi Tanabe 24
3.3 Factor XIII Concentrates 25
3.3.1 Fibrogammin/Corifact (factor XIII) - CSL Behring 25
3.3.2 NovoThirteen/Tretten (catridecacog) - Novo Nordisk 25
3.4 Fibrinogen Concentrates 26
3.4.1 Haemocomplettan P/Riastap (fibrinogen concentrate, human) - CSL Behring 26
3.4.2 Clottafact/Clottagen (fibrinogen concentrate, human) - French Fractionation and Biotechnology Laboratory 27
3.4.3 Other Marketed Fibrinogen Concentrates 27
3.5 Prothrombin Complex Concentrates 27
3.5.1 Beriplex P/N/Confidex/Kcentra (Prothrombin Complex Concentrate [Human]) - CSL Behring 27
3.5.2 Bebulin VH (factor IX complex, vapor heated) - Baxter 27
3.5.3 Cofact (prothrombin complex concentrate) - Sanquin 28
3.5.4 Octaplex 500 (human prothrombin complex) - Octapharma 28
3.5.5 Profilnine SD - Grifols 28
3.5.6 Uman Complex DI - Kedrion 28
4 Pipeline for Critical Care Market 29
4.1 Overview of Pipeline 29
4.2 Promising Pipeline Candidates 30
4.2.1 Octaplex 500 (human prothrombin complex) - Octapharma 30
4.2.2 KW-3357– Kyowa Hakko Kirin 30
4.2.3 Human AT Concentrate - Grifols 30
5 Critical Care Market Forecast to 2020 31
5.1 Geographical Markets 31
5.1.1 Major Developed Markets 31
5.1.2 US 34
5.1.3 Top Five European Countries 36
5.1.4 Japan 40
5.1.5 Canada 42
5.2 Drivers and Barriers 44
5.2.1 Drivers 44
5.2.2 Barriers 45
6 Deals and Strategic Consolidations 47
6.1 Major Deals 47
6.1.1 Octapharma Enters Into an Agreement with Pfizer 47
6.1.2 Grifols to Acquire Blood Transfusion Diagnostics Business from Novartis 47
6.1.3 Shin Poong Pharmaceutical and French Fractionation and Biotechnology Laboratory form a Korea-based Bio-pharmaceutical Joint Venture 47
6.1.4 Bain Capital Acquires 80% Stake in Plasma Resources UK 47
6.1.5 Biomat Acquires Three Plasma Donation Centers from Cangene 48
6.1.6 BioRx Enters into Co-Marketing Agreement with CSL Behring for Corifact 48
6.1.7 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies 48
6.1.8 Shire Enters into Licensing Agreement with Sangamo BioSciences 48
6.1.9 Baxter Completes Acquisition of Rights to OBI-1 and Related Assets from Ipsen and Inspiration Biopharma 48
7 Critical Care Market to 2020 - Appendix 50
7.1 Abbreviations 50
7.2 References 51
7.3 Pipeline Products 54
7.4 Market Forecasts to 2020 55
7.4.1 Major Developed Markets 55
7.4.2 US 56
7.4.3 UK 58
7.4.4 France 59
7.4.5 Germany 61
7.4.6 Italy 62
7.4.7 Spain 64
7.4.8 Japan 65
7.4.9 Canada 67
7.5 Research Methodology 68
7.5.1 Coverage 68
7.5.2 Secondary Research 69
7.5.3 Primary Research 69
7.5.4 Therapeutic Landscape 69
7.5.5 Geographical Landscape 71
7.5.6 Pipeline Analysis 72
7.6 Expert Panel Validation 72
7.7 Contact Us 72
7.8 Disclaimer 72

1.1 List of Tables

Table 1: Critical Care Market, Atryn, Development Timeline, 2007–2013 22
Table 2: Critical Care Market, Global, Pharmaceutical Pipeline, 2014 54
Table 3: Critical Care Market, Major Developed Markets, Market Forecast, 2013–2020 55
Table 4: Critical Care Market, Major Developed Markets, Albumin, Market Forecast, 2013–2020 55
Table 5: Critical Care Market, Major Developed Markets, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 55
Table 6: Critical Care Market, Major Developed Markets, FXIII Concentrates, Market Forecast, 2013–2020 55
Table 7: Critical Care Market, Major Developed Markets, Fibrinogen Concentrates, Market Forecast, 2013–2020 56
Table 8: Critical Care Market, Major Developed Markets, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 56
Table 9: Critical Care Market, US, Market Forecast, 2013–2020 56
Table 10: Critical Care Market, US, Albumin, Market Forecast, 2013–2020 56
Table 11: Critical Care Market, US, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 57
Table 12: Critical Care Market, US, FXIII Concentrates, Market Forecast, 2013–2020 57
Table 13: Critical Care Market, US, Fibrinogen Concentrates, Market Forecast, 2013–2020 57
Table 14: Critical Care Market, US, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 57
Table 15: Critical Care Market, UK, Market Forecast, 2013–2020 58
Table 16: Critical Care Market, UK, Albumin, Market Forecast, 2013–2020 58
Table 17: Critical Care Market, UK, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 58
Table 18: Critical Care Market, UK, FXIII Concentrates, Market Forecast, 2013–2020 58
Table 19: Critical Care Market, UK, Fibrinogen Concentrates, Market Forecast, 2013–2020 59
Table 20: Critical Care Market, UK, Market Forecast, Prothrombin Complex Concentrates, 2013–2020 59
Table 21: Critical Care Market, France, Market Forecast, 2013–2020 59
Table 22: Critical Care Market, France, Albumin, Market Forecast, 2013–2020 59
Table 23: Critical Care Market, France, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 60
Table 24: Critical Care Market, France, FXIII Concentrates, Market Forecast, 2013–2020 60
Table 25: Critical Care Market, France, Fibrinogen Concentrates, Market Forecast, 2013–2020 60
Table 26: Critical Care Market, France, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 60
Table 27: Critical Care Market, Germany, Market Forecast, 2013–2020 61
Table 28: Critical Care Market, Germany, Albumin, Market Forecast, 2013–2020 61
Table 29: Critical Care Market, Germany, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 61
Table 30: Critical Care Market, Germany, FXIII Concentrates, Market Forecast, 2013–2020 61
Table 31: Critical Care Market, Germany, Fibrinogen Concentrates, Market Forecast, 2013–2020 62
Table 32: Critical Care Market, Germany, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 62
Table 33: Critical Care Market, Italy, Market Forecast, 2013–2020 62
Table 34: Critical Care Market, Italy, Albumin, Market Forecast, 2013–2020 62
Table 35: Critical Care Market, Italy, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 63
Table 36: Critical Care Market, Italy, FXIII Concentrates, Market Forecast, 2013–2020 63
Table 37: Critical Care Market, Italy, Fibrinogen Concentrates, Market Forecast, 2013–2020 63
Table 38: Critical Care Market, Italy, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 63
Table 39: Critical Care Market, Spain, Market Forecast, 2013–2020 64
Table 40: Critical Care Market, Spain, Albumin, Market Forecast, 2013–2020 64
Table 41: Critical Care Market, Spain, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 64
Table 42: Critical Care Market, Spain, FXIII Concentrates, Market Forecast, 2013–2020 64
Table 43: Critical Care Market, Spain, Fibrinogen Concentrates, Market Forecast, 2013–2020 65
Table 44: Critical Care Market, Spain, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 65
Table 45: Critical Care Market, Japan, Market Forecast, 2013–2020 65
Table 46: Critical Care Market, Japan, Albumin, Market Forecast, 2013–2020 65
Table 47: Critical Care Market, Japan, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 66
Table 48: Critical Care Market, Japan, FXIII Concentrates, Market Forecast, 2013–2020 66
Table 49: Critical Care Market, Japan, Fibrinogen Concentrates, Market Forecast, 2013–2020 66
Table 50: Critical Care Market, Japan, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 66
Table 51: Critical Care Market, Canada, Market Forecast, 2013–2020 67
Table 52: Critical Care Market, Canada, Albumin, Market Forecast, 2013–2020 67
Table 53: Critical Care Market, Canada, Anti-Thrombin Concentrates, Market Forecast, 2013–2020 67
Table 54: Critical Care Market, Canada, FXIII Concentrates, Market Forecast, 2013–2020 67
Table 55: Critical Care Market, Canada, Fibrinogen Concentrates, Market Forecast, 2013–2020 68
Table 56: Critical Care Market, Canada, Prothrombin Complex Concentrates, Market Forecast, 2013–2020 68

1.2 List of Figures

Figure 1: Critical Care Market, Global, Overall Pipeline Analysis (%), 2013 29
Figure 2: Critical Care Market, Major Developed Markets, Treatment Use Patterns, 2013–2020 32
Figure 3: Critical Care Market, Major Developed Markets, Revenue ($bn), 2013–2020 33
Figure 4: Critical Care Market, US, Treatment Use Patterns, 2013–2020 34
Figure 5: Critical Care Market, US, Annual Cost of Therapy and Revenue, 2013–2020 35
Figure 6: Critical Care Market, Top Five European Countries, Treatment Use Patterns, 2013 and 2020 37
Figure 7: Critical Care Market, Top Five European Countries, Annual Cost of Therapy ($), 2013–2020 38
Figure 8: Critical Care Market, Top Five European Countries, Revenue ($m), 2013–2020 39
Figure 9: Critical Care Market, Japan, Treatment Use Patterns, 2013–2020 40
Figure 10: Critical Care Market, Japan, Annual Cost of Therapy and Revenue, 2013–2020 41
Figure 11: Critical Care Market, Canada, Treatment Use Patterns, 2013–2020 42
Figure 12: Critical Care Market, Canada, Annual Cost of Therapy and Revenue, 2013–2020 43
Figure 13: GBI Research Market Forecasting Model 71